Patient characteristics and GST deletions (crude OR)
| . | (n) . | GSTM1−n (%) . | GSST1−n (%) . | GSTM1−/GSTT1−n (%) . | GSTM1+/GSTT1+n (%) . |
|---|---|---|---|---|---|
| Age, y, n = 106 | ≥60 (58) | 32 (55.2) | 21 (36.2) | 15 (26.8) | 20 (34.5) |
| ≤59 (48) | 13 (27.1) | 9 (18.7) | 4 (8.3) | 30 (62.5) | |
| OR (95% CI) | 3.3 (1.5-7.5) | 2.5 (1-6) | 3.8 (1.2-12) | 0.3 (0.1-0.7) | |
| P | .005 | .05 | .02 | .006 | |
| Sex, n = 106 | Female (51) | 20 (39.2) | 11 (21.6) | 6 (11.8) | 26 (50.9) |
| Male (55) | 25 (45.4) | 19 (34.5) | 13 (23.6) | 24 (43.6) | |
| P | .8 | .2 | .1 | .6 | |
| Previous cancer, n = 106 | Yes (15) | 7 (46.7) | 4 (26.7) | 4 (26.7) | 8 (53.3) |
| No (91) | 38 (41.7) | 26 (28.6) | 15 (16.5) | 42 (46.1) | |
| P | .8 | 1 | .5 | 0.8 | |
| Karyotype, n = 77 | Normal (34) | 12 (35.3) | 10 (29.4) | 7 (20.6) | 19 (55.9) |
| Simple tran*(20) | 11 (55) | 6 (30) | 5 (25) | 11 (55) | |
| Complex (23) | 10 (43.5) | 5 (21.7) | 3 (13) | 8 (34.8) | |
| P | .3 | .8 | .6 | .2 | |
| Favorable (19) | 11 (57.9) | 6 (31.6) | 5 (26.3) | 7 (36.8) | |
| Intermediate (48) | 18 (37.5) | 13 (27.1) | 10 (20.8) | 27 (56.2) | |
| Unfavorable (10) | 4 (40) | 2 (20) | 0 (0) | 4 (40) | |
| P | .3 | .8 | .2 | .2 | |
| FAB, n = 96 | M0-M1 (9) | 4 (44.4) | 2 (22.2) | 2 (22.2) | 5 (55.5) |
| M2 (40) | 16 (40) | 14 (35) | 8 (20) | 17 (42.5) | |
| M3 (11) | 6 (54.5) | 2 (18.2) | 2 (18.2) | 5 (45.4) | |
| M4 (20) | 7 (35) | 3 (15) | 2 (10) | 12 (10) | |
| M5 (8) | 5 (62.5) | 3 (37.5) | 2 (25) | 2 (25) | |
| M6 (8) | 2 (25) | 2 (25) | 1 (12.5) | 5 (62.5) | |
| P | .6 | .6 | .7 | .7 |
| . | (n) . | GSTM1−n (%) . | GSST1−n (%) . | GSTM1−/GSTT1−n (%) . | GSTM1+/GSTT1+n (%) . |
|---|---|---|---|---|---|
| Age, y, n = 106 | ≥60 (58) | 32 (55.2) | 21 (36.2) | 15 (26.8) | 20 (34.5) |
| ≤59 (48) | 13 (27.1) | 9 (18.7) | 4 (8.3) | 30 (62.5) | |
| OR (95% CI) | 3.3 (1.5-7.5) | 2.5 (1-6) | 3.8 (1.2-12) | 0.3 (0.1-0.7) | |
| P | .005 | .05 | .02 | .006 | |
| Sex, n = 106 | Female (51) | 20 (39.2) | 11 (21.6) | 6 (11.8) | 26 (50.9) |
| Male (55) | 25 (45.4) | 19 (34.5) | 13 (23.6) | 24 (43.6) | |
| P | .8 | .2 | .1 | .6 | |
| Previous cancer, n = 106 | Yes (15) | 7 (46.7) | 4 (26.7) | 4 (26.7) | 8 (53.3) |
| No (91) | 38 (41.7) | 26 (28.6) | 15 (16.5) | 42 (46.1) | |
| P | .8 | 1 | .5 | 0.8 | |
| Karyotype, n = 77 | Normal (34) | 12 (35.3) | 10 (29.4) | 7 (20.6) | 19 (55.9) |
| Simple tran*(20) | 11 (55) | 6 (30) | 5 (25) | 11 (55) | |
| Complex (23) | 10 (43.5) | 5 (21.7) | 3 (13) | 8 (34.8) | |
| P | .3 | .8 | .6 | .2 | |
| Favorable (19) | 11 (57.9) | 6 (31.6) | 5 (26.3) | 7 (36.8) | |
| Intermediate (48) | 18 (37.5) | 13 (27.1) | 10 (20.8) | 27 (56.2) | |
| Unfavorable (10) | 4 (40) | 2 (20) | 0 (0) | 4 (40) | |
| P | .3 | .8 | .2 | .2 | |
| FAB, n = 96 | M0-M1 (9) | 4 (44.4) | 2 (22.2) | 2 (22.2) | 5 (55.5) |
| M2 (40) | 16 (40) | 14 (35) | 8 (20) | 17 (42.5) | |
| M3 (11) | 6 (54.5) | 2 (18.2) | 2 (18.2) | 5 (45.4) | |
| M4 (20) | 7 (35) | 3 (15) | 2 (10) | 12 (10) | |
| M5 (8) | 5 (62.5) | 3 (37.5) | 2 (25) | 2 (25) | |
| M6 (8) | 2 (25) | 2 (25) | 1 (12.5) | 5 (62.5) | |
| P | .6 | .6 | .7 | .7 |
Statistical significance obtained using the Fisher exact test (2-sided). Cytogenetic risk groups were defined according to Grimwade et al17 (see “Patients, materials, and methods”).
Simple balanced translocations.